{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T13:59:34Z","timestamp":1781186374790,"version":"3.54.1"},"reference-count":20,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100031665","name":"Medical Research Center, Hamad Medical Corporation","doi-asserted-by":"publisher","award":["IRGC-06-JI-19-205"],"award-info":[{"award-number":["IRGC-06-JI-19-205"]}],"id":[{"id":"10.13039\/100031665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Appl Thromb Hemost"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Previous studies demonstrated the superiority of a genotype-guided warfarin dosing (GWD) method for warfarin initiation. International GWD models such as Gage et al model were validated in diverse populations but Arab patients were not well represented in these studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To derive and validate a GWD model in an Arab population and compare the outcomes to Gage et al model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this cross-sectional study, DNA was collected through saliva kits from a cohort of recruited Arab patients on warfarin\n                      <jats:italic toggle=\"yes\">.<\/jats:italic>\n                      Clinical factors and demographics were recorded and genotyping for\n                      <jats:italic toggle=\"yes\">VKORC1 (\u22121639G<\/jats:italic>\n                      \u2009\n                      <jats:italic toggle=\"yes\">&gt;<\/jats:italic>\n                      \u2009\n                      <jats:italic toggle=\"yes\">A)<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">CYP2C9*2<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">CYP2C9*3<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">CYP4F2*3<\/jats:italic>\n                      was performed. Subjects were randomly divided to derivation and validation cohorts. Simple and Multiple linear regression analyses were used to identify factors associated with warfarin dose and derive a warfarin dosing model. The warfarin dose was also calculated using Gage et al model. Accuracy of the 2 models were compared through the mean absolute error (MAE) and percentage of predicted warfarin doses within 20% of the actual warfarin dose\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The Arab cohort included 405 patients. In the derivation cohort (n\u2009=\u2009270), multiple regression analysis showed a dosing model consisting of\n                      <jats:italic toggle=\"yes\">VKORC1 (\u22121639G<\/jats:italic>\n                      \u2009\n                      <jats:italic toggle=\"yes\">&gt;<\/jats:italic>\n                      \u2009\n                      <jats:italic toggle=\"yes\">A)<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">CYP2C9*2<\/jats:italic>\n                      &amp;\n                      <jats:italic toggle=\"yes\">CYP2C9*3<\/jats:italic>\n                      genotypes, along with other clinical factors (R\n                      <jats:sup>\n                        <jats:xref ref-type=\"bibr\">2<\/jats:xref>\n                      <\/jats:sup>\n                      \u2009=\u200951.6%) (P\u2009&lt;\u20090.05). When compared to Gage et al model, the Arab model had a significantly lower MAE of weekly warfarin dose (9.3\u2009\u00b1\u20097.6\u2005mg\/week vs 12.4\u2009\u00b1\u200910.4\u2005mg\/week,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.03)\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A model derived and validated in an Arab population had better prediction accuracy compared to an internationally validated one.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10760296261439536","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:15:43Z","timestamp":1781010943000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Derivation and Validation of a Genotype- Guided Warfarin Dosing Model in a Mixed Arab Population"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1502-6700","authenticated-orcid":false,"given":"Amr M.","family":"Fahmi","sequence":"first","affiliation":[{"name":"Hamad Medical Corporation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9009-0641","authenticated-orcid":false,"given":"Ahmed El","family":"Bardissy","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2221-4216","authenticated-orcid":false,"given":"Mohamed Omar","family":"Saad","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6387-5419","authenticated-orcid":false,"given":"Islam","family":"Eljilany","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9276-6959","authenticated-orcid":false,"given":"Loulia","family":"Bader","sequence":"additional","affiliation":[{"name":"Qatar University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1594-1199","authenticated-orcid":false,"given":"Hazem","family":"Elewa","sequence":"additional","affiliation":[{"name":"Qatar University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32203-7"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2292"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-019-0083-3"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA0905561\/SUPPL_FILE\/NEJM_CONNOLLY_1139SA1.PDF"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2350"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/PHAR.2158"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/JCPT.13343"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/S11096-022-01386-8"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809329"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311386"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.11469"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168732"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.10"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/CTS.13797"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S322743"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-019-0116-y"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311386"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.11469"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310669"},{"key":"e_1_3_3_21_2","unstructured":"CPIC\u00ae Guideline for Pharmacogenetics-Guided Warfarin Dosing \u2013 CPIC. Accessed July 3 2021. https:\/\/cpicpgx.org\/guidelines\/guideline-for-warfarin-and-cyp2c9-and-vkorc1\/."}],"container-title":["Clinical and Applied Thrombosis\/Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296261439536","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10760296261439536","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296261439536","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T13:17:11Z","timestamp":1781183831000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10760296261439536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":20,"alternative-id":["10.1177\/10760296261439536"],"URL":"https:\/\/doi.org\/10.1177\/10760296261439536","relation":{},"ISSN":["1076-0296","1938-2723"],"issn-type":[{"value":"1076-0296","type":"print"},{"value":"1938-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"10760296261439536"}}